8-K: Celcuity's Gedatolisib Trial Shows Doubled Survival in Breast Cancer

Celcuity Inc. announced detailed Phase 3 VIKTORIA-1 trial results for gedatolisib, showing a significant improvement in progression-free survival for advanced breast cancer patients.

Summary

• Celcuity Inc. reported detailed efficacy and safety results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib.
• The gedatolisib-triplet regimen demonstrated a statistically significant and clinically meaningful improvement in median progression-free survival (PFS), nearly doubling the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant.
• Median PFS for the gedatolisib-triplet was 11.1 months versus 5.6 months for alpelisib plus fulvestrant (Hazard Ratio [HR] of 0.50).
• The objective response rate (ORR) for the gedatolisib-triplet was 48.9%, compared to 26.0% for alpelisib plus fulvestrant.
• Median duration of response (DOR) for the gedatolisib-triplet was 15.7 months, compared to 7.5 months for alpelisib plus fulvestrant.
• The gedatolisib-doublet regimen also showed a significant improvement in median PFS, more than doubling it to 11.3 months versus 5.6 months (HR=0.51).
• The ORR for the gedatolisib-doublet was 35.7% with a median DOR of 24.2 months.
• The company plans to submit these data to the FDA as a supplemental New Drug Application (sNDA) and anticipates a potential FDA approval and commercial launch in Q3 2026.
• The FDA has granted Priority Review for gedatolisib in a different patient population (PIK3CA wild-type) with a PDUFA goal date of July 17, 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement due to the statistically significant and clinically meaningful improvements in key efficacy endpoints (PFS, ORR, DOR) and favorable safety profile compared to the current standard of care.

Positives

• Gedatolisib-triplet regimen nearly doubled median progression-free survival (PFS) to 11.1 months from 5.6 months compared to alpelisib plus fulvestrant.
• Gedatolisib-triplet regimen showed a statistically significant improvement in PFS with a hazard ratio of 0.50 (p<0.0001).
• Objective response rate (ORR) for the gedatolisib-triplet was 48.9%, significantly higher than 26.0% for the comparator.
• Median duration of response (DOR) for the gedatolisib-triplet was 15.7 months, more than double the 7.5 months of the comparator.
• Gedatolisib-doublet regimen also demonstrated a significant PFS improvement, more than doubling it to 11.3 months from 5.6 months.
• The gedatolisib-triplet achieved the highest median PFS reported in any Phase 3 trial for this patient population receiving second-line endocrine therapy.
• The gedatolisib-triplet achieved the highest ORR reported in any Phase 3 trial for this patient population receiving second-line endocrine therapy.
• Gedatolisib regimens were generally well-tolerated with lower treatment discontinuation rates compared to alpelisib plus fulvestrant.

Negatives

• The most common Grade 3+ treatment-related adverse event (TRAE) for the gedatolisib-triplet was neutropenia (58.8%).
• One Grade 5 TRAE related to palbociclib was reported in the gedatolisib-triplet group.
• While overall survival data is immature, it showed promising trends, indicating it's not yet a definitive positive outcome.

Risks

• Clinical results are based on ongoing analysis and may change following a more comprehensive review.
• Unforeseen delays in clinical trials or the FDA's review of the NDA for gedatolisib.
• Ability to obtain and maintain regulatory approvals to commercialize gedatolisib.
• Market acceptance of gedatolisib.
• Development of therapies and tools competitive with gedatolisib.
• Ability to access capital upon favorable terms.
• Risks detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings.

Future Outlook

Celcuity anticipates submitting data to the FDA for a supplemental New Drug Application (sNDA) and expects potential FDA approval and commercial launch of gedatolisib in the third quarter of 2026. The FDA has granted Priority Review for gedatolisib in a different patient population (PIK3CA wild-type) with a PDUFA goal date of July 17, 2026.

Management Comments

• "By comprehensively blocking the PI3K/AKT/mTOR, or PAM, pathway, gedatolisib combined with fulvestrant, with or without palbociclib, showed it can offer these patients two times the likelihood of survival without disease progression or death relative to a single-target inhibitor of the PAM pathway."
• "With these results, the gedatolisib regimens, if approved, represent a new potential standard of care for patients with HR+, HER2-negative, PIK3CA mutant advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor."
• "These safety results compare very favorably to those from the patient group treated with alpelisib and fulvestrant, which we believe reflects the benefit of gedatolisibs multi-target mechanism of action, pharmacokinetic profile, and intravenous administration."
• "It is rare in oncology for a targeted therapy to offer both improved efficacy and better safety results relative to another drug in its class. This second positive Phase 3 data readout further underscores the broad potential of multi-target PAM inhibition and increases our excitement about our two Phase 3 trials in the first-line setting for HR+/HER2- advanced breast cancer."
• "We are on track to launch gedatolisib commercially, in anticipation of its potential FDA approval in the third quarter of 2026, and we look forward to the possibility of bringing this important therapy to physicians treating patients with advanced breast cancer."

Industry Context

StockSavvy.ai notes that Celcuity's results in the VIKTORIA-1 trial position gedatolisib as a potentially significant advancement in the treatment of HR+/HER2- advanced breast cancer, particularly for patients who have progressed on CDK4/6 inhibitors. The demonstration of superiority over another PI3K inhibitor (alpelisib) and achieving record PFS and ORR metrics in Phase 3 trials highlights the potential of multi-target PAM pathway inhibition, a key area of research in oncology.

Comparison to Industry Standards

• The median PFS of 11.1 months for the gedatolisib-triplet is the highest reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving a regimen including endocrine therapy as second-line treatment.
• The objective response rate (ORR) of 48.9% for the gedatolisib-triplet is the highest reported by any Phase 3 clinical trial for a regimen including endocrine therapy in second-line HR+/HER2- ABC.
• The trial is the first Phase 3 trial to demonstrate superiority of one PAM inhibitor versus another in this patient population.
• The gedatolisib-triplet's median PFS of 11.1 months is nearly double the 5.6 months achieved by alpelisib plus fulvestrant.
• The gedatolisib-doublet's median PFS of 11.3 months is also more than double the 5.6 months achieved by alpelisib plus fulvestrant.

Stakeholder Impact

• Shareholders: Positive impact expected from potential approval and commercialization of a novel cancer therapy, potentially leading to increased company valuation.
• Patients: Significant positive impact through the potential availability of a new, more effective treatment option for advanced breast cancer.
• Healthcare Providers: Potential to offer a new standard of care for a specific patient population, improving treatment outcomes.
• Competitors: Increased competitive pressure as gedatolisib demonstrates superior efficacy in a key indication.

Next Steps

• Submit VIKTORIA-1 PIK3CA MT cohort data to the U.S. FDA as a supplemental New Drug Application (sNDA).
• Submit VIKTORIA-1 data to other regulatory authorities following the sNDA submission.
• Anticipate potential FDA approval and commercial launch of gedatolisib in Q3 2026.
• Continue development of gedatolisib, including future subcutaneous formulations.
• Present detailed results at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Dates

Recommendation

The strong positive results from the Phase 3 VIKTORIA-1 trial, demonstrating a doubling of progression-free survival and significantly improved response rates with a generally well-tolerated safety profile, position gedatolisib as a potential best-in-class therapy for a significant unmet need in advanced breast cancer. Coupled with the FDA's Priority Review for a related indication and an anticipated Q3 2026 launch, the outlook is highly favorable, suggesting substantial upside potential.

Keywords

gedatolisib, breast cancer, VIKTORIA-1, Phase 3 trial, PIK3CA, HR+/HER2-, metastatic breast cancer, clinical trial results